Does the media favor CELC or BBIO?

In the previous week, Celcuity had 2 more articles in the media than BridgeBio Pharma. MarketBeat recorded 10 mentions for Celcuity and 8 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.87 beat Celcuity's score of 0.25 indicating that BridgeBio Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celcuity 4 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BridgeBio Pharma 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ASND or CELC?

In the previous week, Celcuity had 5 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 10 mentions for Celcuity and 5 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 0.67 beat Celcuity's score of 0.25 indicating that Ascendis Pharma A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Celcuity 4 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, EXEL or CELC?

Exelixis has higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exelixis $2.32B 5.72 $782.57M $3.18 16.60 Celcuity N/A N/A -$177.04M -$3.90 N/A

Is EXEL or CELC more profitable?

Exelixis has a net margin of 35.33% compared to Celcuity's net margin of 0.00%. Exelixis' return on equity of 42.17% beat Celcuity's return on equity. Company Net Margins Return on Equity Return on Assets Exelixis 35.33% 42.17% 31.76% Celcuity N/A -244.61% -50.22%

Does the media favor EXEL or CELC?

In the previous week, Exelixis had 32 more articles in the media than Celcuity. MarketBeat recorded 42 mentions for Exelixis and 10 mentions for Celcuity. Exelixis' average media sentiment score of 0.30 beat Celcuity's score of 0.25 indicating that Exelixis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 11 Very Positive mention(s) 2 Positive mention(s) 12 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Neutral Celcuity 4 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ARWR or CELC?

In the previous week, Arrowhead Pharmaceuticals had 21 more articles in the media than Celcuity. MarketBeat recorded 31 mentions for Arrowhead Pharmaceuticals and 10 mentions for Celcuity. Celcuity's average media sentiment score of 0.25 beat Arrowhead Pharmaceuticals' score of 0.06 indicating that Celcuity is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 9 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Celcuity 4 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer BMRN or CELC?

In the previous week, BioMarin Pharmaceutical had 19 more articles in the media than Celcuity. MarketBeat recorded 29 mentions for BioMarin Pharmaceutical and 10 mentions for Celcuity. BioMarin Pharmaceutical's average media sentiment score of 0.77 beat Celcuity's score of 0.25 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioMarin Pharmaceutical 9 Very Positive mention(s) 3 Positive mention(s) 11 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Celcuity 4 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Celcuity (CELC) Competitors

$91.26 -1.53 (-1.64%)

As of 01:46 PM Eastern

Compare

CELC vs. BBIO, ASND, EXEL, ARWR, and BMRN

Should you buy Celcuity stock or one of its competitors? MarketBeat compares Celcuity with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Celcuity include BridgeBio Pharma (BBIO), Ascendis Pharma A/S (ASND), Exelixis (EXEL), Arrowhead Pharmaceuticals (ARWR), and BioMarin Pharmaceutical (BMRN). These companies are all part of the "biotechnology" industry.

How does Celcuity compare to BridgeBio Pharma?

Celcuity (NASDAQ:CELC) and BridgeBio Pharma (NASDAQ:BBIO) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, media sentiment, analyst recommendations, dividends, earnings and institutional ownership.

Celcuity has higher earnings, but lower revenue than BridgeBio Pharma. Celcuity is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celcuity	N/A	N/A	-$177.04M	-$3.90	N/A
BridgeBio Pharma	$502.08M	33.12	-$724.93M	-$3.74	N/A

63.3% of Celcuity shares are held by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are held by institutional investors. 13.3% of Celcuity shares are held by insiders. Comparatively, 14.2% of BridgeBio Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Celcuity has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -124.42%. BridgeBio Pharma's return on equity of 0.00% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celcuity	N/A	-244.61%	-50.22%
BridgeBio Pharma	-124.42%	N/A	-65.81%

Celcuity presently has a consensus price target of $155.18, indicating a potential upside of 70.05%. BridgeBio Pharma has a consensus price target of $97.33, indicating a potential upside of 14.44%. Given Celcuity's higher possible upside, research analysts clearly believe Celcuity is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celcuity	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	19 Buy rating(s)	0 Strong Buy rating(s)	2.82

Celcuity has a beta of 0.21, suggesting that its stock price is 79% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market.

In the previous week, Celcuity had 2 more articles in the media than BridgeBio Pharma. MarketBeat recorded 10 mentions for Celcuity and 8 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.87 beat Celcuity's score of 0.25 indicating that BridgeBio Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celcuity	4 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BridgeBio Pharma	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

BridgeBio Pharma beats Celcuity on 9 of the 14 factors compared between the two stocks.

How does Celcuity compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Celcuity (NASDAQ:CELC) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings.

Celcuity has lower revenue, but higher earnings than Ascendis Pharma A/S. Celcuity is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	19.31	-$258M	$8.67	29.08
Celcuity	N/A	N/A	-$177.04M	-$3.90	N/A

Ascendis Pharma A/S has a beta of 0.39, meaning that its share price is 61% less volatile than the broader market. Comparatively, Celcuity has a beta of 0.21, meaning that its share price is 79% less volatile than the broader market.

Ascendis Pharma A/S currently has a consensus price target of $296.12, suggesting a potential upside of 17.46%. Celcuity has a consensus price target of $155.18, suggesting a potential upside of 70.05%. Given Celcuity's higher possible upside, analysts clearly believe Celcuity is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	3.06
Celcuity	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Ascendis Pharma A/S has a net margin of 57.87% compared to Celcuity's net margin of 0.00%. Ascendis Pharma A/S's return on equity of 0.00% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	57.87%	N/A	-8.37%
Celcuity	N/A	-244.61%	-50.22%

63.3% of Celcuity shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by company insiders. Comparatively, 13.3% of Celcuity shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Celcuity had 5 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 10 mentions for Celcuity and 5 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 0.67 beat Celcuity's score of 0.25 indicating that Ascendis Pharma A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Celcuity	4 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Ascendis Pharma A/S beats Celcuity on 12 of the 16 factors compared between the two stocks.

How does Celcuity compare to Exelixis?

Exelixis (NASDAQ:EXEL) and Celcuity (NASDAQ:CELC) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk and valuation.

Exelixis currently has a consensus price target of $49.79, indicating a potential downside of 5.69%. Celcuity has a consensus price target of $155.18, indicating a potential upside of 70.05%. Given Celcuity's stronger consensus rating and higher probable upside, analysts plainly believe Celcuity is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	2 Sell rating(s)	10 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.26
Celcuity	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Exelixis has a beta of 0.44, indicating that its stock price is 56% less volatile than the broader market. Comparatively, Celcuity has a beta of 0.21, indicating that its stock price is 79% less volatile than the broader market.

85.3% of Exelixis shares are owned by institutional investors. Comparatively, 63.3% of Celcuity shares are owned by institutional investors. 2.6% of Exelixis shares are owned by insiders. Comparatively, 13.3% of Celcuity shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Exelixis has a net margin of 35.33% compared to Celcuity's net margin of 0.00%. Exelixis' return on equity of 42.17% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
Celcuity	N/A	-244.61%	-50.22%

In the previous week, Exelixis had 32 more articles in the media than Celcuity. MarketBeat recorded 42 mentions for Exelixis and 10 mentions for Celcuity. Exelixis' average media sentiment score of 0.30 beat Celcuity's score of 0.25 indicating that Exelixis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	11 Very Positive mention(s)	2 Positive mention(s)	12 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Neutral
Celcuity	4 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Exelixis has higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	5.72	$782.57M	$3.18	16.60
Celcuity	N/A	N/A	-$177.04M	-$3.90	N/A

Summary

Exelixis beats Celcuity on 11 of the 15 factors compared between the two stocks.

How does Celcuity compare to Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Celcuity (NASDAQ:CELC) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

Celcuity has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -47.79%. Arrowhead Pharmaceuticals' return on equity of -60.06% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%
Celcuity	N/A	-244.61%	-50.22%

62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. Comparatively, 63.3% of Celcuity shares are owned by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are owned by company insiders. Comparatively, 13.3% of Celcuity shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Arrowhead Pharmaceuticals currently has a consensus price target of $97.33, indicating a potential upside of 10.39%. Celcuity has a consensus price target of $155.18, indicating a potential upside of 70.05%. Given Celcuity's stronger consensus rating and higher probable upside, analysts plainly believe Celcuity is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Celcuity	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

In the previous week, Arrowhead Pharmaceuticals had 21 more articles in the media than Celcuity. MarketBeat recorded 31 mentions for Arrowhead Pharmaceuticals and 10 mentions for Celcuity. Celcuity's average media sentiment score of 0.25 beat Arrowhead Pharmaceuticals' score of 0.06 indicating that Celcuity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	9 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Celcuity	4 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Arrowhead Pharmaceuticals has higher revenue and earnings than Celcuity. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Celcuity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$669.50M	18.55	-$1.63M	-$2.25	N/A
Celcuity	N/A	N/A	-$177.04M	-$3.90	N/A

Arrowhead Pharmaceuticals has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market. Comparatively, Celcuity has a beta of 0.21, suggesting that its stock price is 79% less volatile than the broader market.

Summary

Celcuity beats Arrowhead Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Celcuity compare to BioMarin Pharmaceutical?

BioMarin Pharmaceutical (NASDAQ:BMRN) and Celcuity (NASDAQ:CELC) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

BioMarin Pharmaceutical has higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioMarin Pharmaceutical	$3.22B	4.11	$348.90M	$0.37	184.79
Celcuity	N/A	N/A	-$177.04M	-$3.90	N/A

BioMarin Pharmaceutical has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market. Comparatively, Celcuity has a beta of 0.21, meaning that its share price is 79% less volatile than the broader market.

BioMarin Pharmaceutical presently has a consensus target price of $88.00, indicating a potential upside of 28.71%. Celcuity has a consensus target price of $155.18, indicating a potential upside of 70.05%. Given Celcuity's stronger consensus rating and higher possible upside, analysts plainly believe Celcuity is more favorable than BioMarin Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioMarin Pharmaceutical	0 Sell rating(s)	8 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.71
Celcuity	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

In the previous week, BioMarin Pharmaceutical had 19 more articles in the media than Celcuity. MarketBeat recorded 29 mentions for BioMarin Pharmaceutical and 10 mentions for Celcuity. BioMarin Pharmaceutical's average media sentiment score of 0.77 beat Celcuity's score of 0.25 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioMarin Pharmaceutical	9 Very Positive mention(s)	3 Positive mention(s)	11 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Celcuity	4 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. Comparatively, 63.3% of Celcuity shares are owned by institutional investors. 0.7% of BioMarin Pharmaceutical shares are owned by company insiders. Comparatively, 13.3% of Celcuity shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

BioMarin Pharmaceutical has a net margin of 2.14% compared to Celcuity's net margin of 0.00%. BioMarin Pharmaceutical's return on equity of 5.32% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioMarin Pharmaceutical	2.14%	5.32%	3.69%
Celcuity	N/A	-244.61%	-50.22%

Summary

BioMarin Pharmaceutical beats Celcuity on 13 of the 16 factors compared between the two stocks.

Get Celcuity News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CELC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CELC vs. The Competition

Export

Metric	Celcuity	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.46B	$3.72B	$7.04B	$12.92B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-23.42	9.08	269.97	24.82
Price / Sales	N/A	1,268.38	650.66	108.09
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	42.05	17.65	11.26	6.44
Net Income	-$177.04M	-$13.25M	$3.45B	$347.27M
7 Day Performance	4.03%	5.33%	3.62%	2.55%
1 Month Performance	-15.17%	-1.83%	-0.56%	-1.02%
1 Year Performance	98.90%	61.05%	77.38%	23.33%

Celcuity Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CELC Celcuity	2.9883 of 5 stars	$91.26 -1.6%	$155.18 +70.1%	+102.2%	$4.46B	N/A	N/A	40	Upcoming Earnings
BBIO BridgeBio Pharma	2.7282 of 5 stars	$80.96 +1.3%	$95.21 +17.6%	+81.4%	$15.82B	$502.08M	N/A	400
ASND Ascendis Pharma A/S	4.6781 of 5 stars	$241.60 -0.8%	$296.72 +22.8%	+33.4%	$15.07B	$814.57M	27.87	1,189	Positive News
EXEL Exelixis	2.2323 of 5 stars	$55.87 +1.5%	$49.50 -11.4%	+43.3%	$14.03B	$2.32B	18.54	1,077	Earnings Report Analyst Downgrade
ARWR Arrowhead Pharmaceuticals	1.7782 of 5 stars	$87.75 +2.0%	$96.92 +10.4%	+433.8%	$12.36B	$622.01M	N/A	400	Earnings Report Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CELC) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Celcuity (CELC) Competitors

CELC vs. BBIO, ASND, EXEL, ARWR, and BMRN

How does Celcuity compare to BridgeBio Pharma?

Summary

How does Celcuity compare to Ascendis Pharma A/S?

Summary

How does Celcuity compare to Exelixis?

Summary

How does Celcuity compare to Arrowhead Pharmaceuticals?

Summary

How does Celcuity compare to BioMarin Pharmaceutical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELC vs. The Competition

Celcuity Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Celcuity (CELC) Competitors

CELC vs. BBIO, ASND, EXEL, ARWR, and BMRN

How does Celcuity compare to BridgeBio Pharma?

Which has higher valuation and earnings, CELC or BBIO?

Do institutionals and insiders hold more shares of CELC or BBIO?

Is CELC or BBIO more profitable?

Do analysts prefer CELC or BBIO?

Which has more risk & volatility, CELC or BBIO?

Does the media favor CELC or BBIO?

Summary

How does Celcuity compare to Ascendis Pharma A/S?

Which has stronger valuation and earnings, ASND or CELC?

Which has more risk & volatility, ASND or CELC?

Do analysts rate ASND or CELC?

Is ASND or CELC more profitable?

Do insiders and institutionals have more ownership in ASND or CELC?

Does the media prefer ASND or CELC?

Summary

How does Celcuity compare to Exelixis?

Do analysts recommend EXEL or CELC?

Which has more risk & volatility, EXEL or CELC?

Do insiders and institutionals believe in EXEL or CELC?

Is EXEL or CELC more profitable?

Does the media favor EXEL or CELC?

Which has higher earnings & valuation, EXEL or CELC?

Summary

How does Celcuity compare to Arrowhead Pharmaceuticals?

Is ARWR or CELC more profitable?

Do institutionals and insiders have more ownership in ARWR or CELC?

Do analysts prefer ARWR or CELC?

Does the media favor ARWR or CELC?

Which has stronger valuation and earnings, ARWR or CELC?

Which has more volatility and risk, ARWR or CELC?

Summary

How does Celcuity compare to BioMarin Pharmaceutical?

Which has stronger valuation & earnings, BMRN or CELC?

Which has more volatility & risk, BMRN or CELC?

Do analysts rate BMRN or CELC?

Does the media prefer BMRN or CELC?

Do institutionals & insiders believe in BMRN or CELC?

Is BMRN or CELC more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELC vs. The Competition

Celcuity Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools